


# Framework for Provision of Pain Services for Adults Across the UK with Cancer or Life-limiting Disease





The Royal College of Radiologists

This document has been reviewed and endorsed by The Faculty of Clinical Oncology of The Royal College of Radiologists

# FRAMEWORK FOR PROVISION OF PAIN SERVICES FOR ADULTS ACROSS THE UK WITH CANCER OR LIFE-LIMITING DISEASE

## Faculty of Pain Medicine:

Prof Michael Bennett      Project lead, FPM and Association for Palliative Medicine

Dr Barry Miller              Dean

Dr Anna Weiss                Lead on Core Standards

Dr Paul Wilkinson          Chair, Professional Standards Committee

## Association for Palliative Medicine

Dr Andrew Davies            President

## Association of Cancer Physicians

Dr Tania Tillett              Consultant Medical Oncologist

## The Royal College of Radiologists (Faculty of Clinical Oncology)

Dr Elizabeth Toy              Consultant Clinical Oncologist

## Independent Chair

Prof Baroness Finlay of Llandaff

## EXECUTIVE SUMMARY

1. This document presents a framework and operational guidance for improving pain services for adults across the UK with cancer or life-limiting disease.
2. This guidance is timely because of the importance to the public of pain associated with cancer and life-limiting disease, the evidence of under-treatment or poor access to care, the need to show evidence of better pain management in CQC inspections from 2016, and the need to meet new commissioning requirements for managing complex interventions (e.g. intrathecal pumps).
3. The guidance is designed to (a) inform and stimulate delivery of Level 3 services (linked Palliative Medicine and Specialist Pain Management) in secondary care offered by most district level hospitals, and (b) identify referral pathways to Level 4 services (Highly Specialist Pain Management).
4. Each of the 211 Clinical Commissioning Groups (England), 14 NHS Boards (Scotland), 7 Health Boards (Wales), or 5 Health and Social Care Trusts (Northern Ireland) will ensure direct and rapid access to Level 3 services which will:
  - a. Comprise a Consultant in Pain Medicine and a Consultant in Palliative Medicine leading a weekly multi-disciplinary meeting which includes nursing, physiotherapy and other health professionals, and covering outpatient and interventional sessions
  - b. Be provided for patients with persistent or recurrent pain not adequately managed in primary care or generalist settings.
  - c. Undertake assessment including confirmation of pain diagnosis and pain aetiology (using ICD-11 classification system), the need for further investigations, and an agreed management plan consistent with patient goals and preferences.
  - d. Offer local expertise in management of complex analgesic combinations (methadone, ketamine) including high dose opioids, and interventional procedures including peripheral nerve blocks (e.g. coeliac plexus, lumbar sympathectomy) and intrathecal neurolytic block. Other procedures may be offered within the competency of the Consultant in Pain Medicine and the expertise of staff and local infrastructure such as external spinal infusions
  - e. Determine onward referral to Level 4 (Highly Specialist Pain Management) services for those patients requiring direct referral to Level 4 or not responding to Level 3 pain services and who have a realistic possibility of improvement within Level 4 service.
5. Services should meet the standards and outcomes for patients described in the Faculty of Pain Medicine's 'Core Standards for Pain Management Services in the UK' relating to cancer pain and the European Pain Federation's standards for cancer-related pain.
6. Leads for Level 3 and Level 4 Specialist Pain Management services should have Advanced Pain Training or equivalent. Core competencies for managing cancer pain are described by the Faculty of Pain medicine and should be incorporated across all oncology and palliative medicine training curricula. Access to Advanced Pain Training should be available for palliative medicine and oncology specialties.

## 1. BACKGROUND

### 1.1. Cancer-related pain remains a challenge

Each year 350,000 people in the UK are diagnosed with cancer and 160,000 people die from this disease, which is expected to rise to 193,000 deaths by 2030 [1]. Pain is the commonest symptom of cancer at diagnosis [2]. Following chemotherapy, 60% of patients will experience peripheral neuropathic pain 3 months after treatment, persisting in 30% at 6 months. Overall, between 33% and 40% of cancer survivors (people with cancer whose curative treatment was completed) suffer from chronic pain [3,4]. Evidence suggests that 45-56% of patients with advanced incurable cancer (72,000 to 89,600 each year in the UK) experience moderate to severe intensity pain before they die, often for many months [2,5].

Longitudinal interview studies with cancer patients reveal that pain is very dynamic and complex, and that pain control is often a trial and error process that requires continuous work [6]. Bender et al [7] identified that patients are keen to understand the cause of their cancer pain, what to expect, options for pain control (including addressing concerns about strong opioids), and how to cope with cancer pain including talking with others and finding help. Although patients understandably express that they want to be pain free, in general they do not actually expect their pain to go completely [8].

Patients attempt to reduce interference from both pain and the cognitive effects of analgesia to maintain as much function as possible [9,10]. This often leads to trade-offs between pain and analgesia, impacting on medication adherence. Most patients seem to determine whether their pain is controlled by whether they can perform activities or tasks and maintain relationships with family or friends [8].

### 1.2. Evidence of persisting under-treatment

Greco et al [11] estimated the adequacy of treatment for cancer pain and identified that approximately 32% of patients were not receiving analgesia proportionate to their pain severity. This potentially represents an improvement on an earlier estimate [12] which suggested 43% of cancer patients were undertreated. Nevertheless, a considerable number of patients with cancer pain are not well managed. A retrospective cohort study from the UK identified for the first time the relatively short duration of strong opioid treatment in 6080 patients who died from cancer [13]. This study showed that only 48% of patients received a strong opioid before death (consistent with a previous UK study, [14]) and that median treatment duration was 9 weeks, suggesting that earlier pain assessment might lead to improved outcomes for patients.

Patients at the end of life report their preferred place of care and death is home (or not in hospital) [15]. The National Survey of Bereaved People (VOICES) has evaluated the perceptions of the care given to recently deceased persons (not just those with cancer) since 2011 [16]. In 2015, only 18% reported that pain was controlled 'completely, all the time' at home compared with 38% in hospital and 63% in hospice. Not surprisingly, uncontrolled pain is the most frequent reason for community-based cancer patients to contact out of hours primary care services [17].

Many patients with pain related to cancer or life-limiting disease can be satisfactorily managed within primary care by their General Practitioner. However, a significant minority with persistent pain will need additional assessment and multidisciplinary management either due to the intensity of their pain, significant distress or the impact on functioning and substantial co-morbidities. Evidence indicates that improved cancer pain management is associated with integration with palliative care [18-20]. Closer integration of pain management, palliative care and oncology services

is therefore needed to improve access to pain management for patients with pain related to cancer or life-limiting disease.

## 2. THE NEED FOR GUIDANCE

### 2.1. National policy context

In 2008, the Department of Health published a strategy for end of life care as it recognised that many people did not have what could be described as a ‘good death’: being treated as an individual with dignity and respect, being without pain and other symptoms, being in familiar surroundings, and being in the company of close family or friends [21]. A NICE quality standard was subsequently issued in 2011 to define and support high quality end of life care, specifically including pain management [22]. The Care Quality Commission has emphasised the urgent need to improve end of life care services in the NHS because of unacceptable variation in access to and experience of care [23].

In 2016, The British Medical Association interviewed 269 members of the public and 237 doctors regarding the provision of end of life care by the NHS [24]. For both the public and doctors, pain was the most feared aspect of dying and underlining the importance of good pain control at the end of life. In a follow-up review of analgesic use for pain management at the end of life, the British Medical Association identified several recommendations for improving patients’ experiences [25]. These included improving access to opioids, improved access to palliative care and pain services particularly for those with non-cancer diseases (at least one third of whom experience pain[26]), and better support for generalists from palliative care and pain specialists.

The British Pain Society published guidance on cancer pain in 2010 [27,28] that concluded by calling for:

- (a) a multimodal approach to the management of cancer pain, and not just towards the end of life, but also pain at diagnosis, as a consequence of cancer therapies and in cancer survivors
- (b) improvements in the management of cancer pain by better collaboration between the disciplines of oncology, pain medicine and palliative medicine in terms of funding, time for joint working and the education of all healthcare professionals involved in the treatment of cancer pain.

### 2.2. Existing integration and access to care

A recent review has summarised the current evidence regarding integration of pain management and palliative care services in the UK [29]. The review concluded that there was an ‘inconsistent partnership between the specialties of pain medicine and palliative medicine’. A variety of reasons were proposed for this under-utilisation which included a lack of formal structures, geographical isolation of hospice units, different management and governance structures between the services and a lack of experience among palliative medicine physicians.

The British Pain Society and Association for Palliative Medicine surveyed prominent pain and palliative medicine units across the UK and Ireland in 2015, to gather information on their current service provision and to identify good examples of closer integration [unpublished data]. Telephone interviews with 9 pain specialists and 9 palliative medicine specialists were conducted (40% response rate). Half of respondents stated they had a formal arrangement for integrated working. On average, palliative medicine specialists referred one patient per month to specialist pain services, but pain

services reported a higher frequency of referrals suggesting that direct referral from oncology services is an important source of referral.

Palliative medicine consultants felt that working in a joint manner was helpful, and they would be open to the idea of working jointly. This is in marked contrast to previous surveys that suggested palliative medicine teams felt they needed little further input from pain services. However, most respondents felt joint working must be based on a clear evidence base. Both palliative medicine and pain specialists felt that integrated and joint services must be based on a national specification rather than ad hoc arrangements, which from their experience was based on an individual with an interest setting up a service. This was felt to have led to the national variation in service provision. It was also apparent that specific time allocated in job plans was an essential part to forming a successful cancer pain service.

There remains a consensus that patients are often referred too late to specialist pain services to benefit optimally from the available expertise. Anecdotally, there are reports of successful structured and funded collaboration between specialist palliative care and pain services, but this is not widespread. The scope for collaboration on clinical, research and teaching initiatives is enormous and remains seriously under-developed.

One barrier to earlier access to specialised pain management services is timing of referral to palliative care services. Data from 64 of 200 UK hospices on 42,758 patients that died showed that median timing of referral to community palliative care services before death was 48 days. Older age and non-cancer diagnoses were associated with significantly shorter duration of care [30].

### 2.3. Aims and objectives of new guidance

Existing standards have been important in highlighting the need for closer integration between pain management and palliative care services [28] and specifying that multidisciplinary teams are required for the delivery of specialised pain services [31,32], including management of intrathecal pumps [33]. Standards and guidance also describe good clinical care and outcomes for patients with cancer pain in the UK [34-36]. Finally, competencies exist for individuals involved in delivering cancer pain management [37]. However, there is no supporting guidance for NHS Trusts or existing pain management, oncology and palliative care services on how an integrated service might be configured, how it might be commissioned, and what activities it should undertake.

New guidance is required to collate existing publications into a pain service specification for clinicians and commissioners. This guidance is timely because of the importance to the public of pain associated with advanced disease [24,25], the evidence of under-treatment or poor access to care [11,13,16], the need to show evidence of better pain management in CQC inspections from 2016 [36], and the need to meet updated commissioning requirements for Highly Specialist Pain Management Services [33].

A framework for managing pain in cancer or life-limiting disease is presented below, adapted from recommendations for psychological services within NICE Guidance on Cancer Services [38]. The guidance in this document is designed particularly to inform and stimulate delivery of Level 3 services in secondary care. This is likely to have the greatest impact with least cost in relation to meeting the needs of patients with cancer and life-limiting disease.

Closer integration of pain management, oncology and palliative care services can result in more comprehensive pain assessment and a wider range of Level 3 and Level 4 for patients comprising pharmacological, interventional, rehabilitative and psychological approaches. Although this will

certainly benefit patients with more complex pain syndromes, those with less complex pain but who require more skilful balancing of analgesic medicines might be helped too.

### Framework for pain management in cancer and life-limiting disease

LEVEL	HEALTHCARE GROUP	ASSESSMENT	INTERVENTION
<b>1</b>	<b>All health care professionals</b>	Recognition of pain Screening for pain	Effective information giving and compassionate support Referral to oncology or palliative care professional Initiation of conventional analgesia
<b>2</b>	<b>All oncology and palliative care physicians and advanced practitioners</b>	Assessment of pain Diagnosis of pain disorder	Management and titration of conventional analgesia Support for self-management Referral to Specialist Pain Management as required
<b>3</b>	<b>Linked Palliative care and Specialist Pain Management in secondary care settings</b>  Consultant in Pain Medicine jointly working with Consultant in Palliative Medicine, both with accredited training in pain management in cancer and other advanced diseases  Access via referral from primary or secondary care professionals	Diagnosis of complex pain syndromes	Management of complex analgesic combinations, including high dose opioids  Interventional procedures of varying complexity depending on local skills and resources  Support for self-management Referral to Adult Highly Specialist Pain Management as required
<b>4</b>	<b>Adult Highly Specialist Pain Management in tertiary care settings</b>  Specialist services across the UK with Consultant teams in Pain Medicine and Palliative Medicine  Access only via referral from Level 3 services	Diagnosis of complex pain syndromes	Interventional procedures not available at local Level 3 and including some more complex procedures (e.g. implanted intrathecal drug delivery systems, cordotomy and other neurolytic procedures)  Rehabilitative programmes Managing distress or other behaviours related to poorly controlled medication use



## 3. THE GUIDANCE

### 3.1. Service eligibility

Pain services for patients with cancer and life-limiting disease will follow the existing provision of chronic pain management services configured for secondary and tertiary care.

Level 3 services comprise specialist pain services along with a formal link with Palliative Medicine as described above. Specialist pain services are described in publications by the Faculty of Pain Medicine [32] and the Royal College of General Practitioners [39] and comprise those offered by most district level hospitals with access via primary and secondary care referral. Level 3 services will be for:

Patients with persistent or recurrent pain not adequately managed in primary care.

Patients whose pain is causing significant distress or functional impairment.

Patients who may benefit from joint management with specialist pain and palliative care.

Patients with pain directly associated with cancer or indirectly from its treatments, and other life-limiting disease for which local skills (including interventional options) are available

‘Cancer survivors’ are patients with cancer who have undergone treatment (e.g. surgery, chemotherapy or radiotherapy) and are deemed to be living with and beyond cancer but who have persistent pain.

Level 4 services are described in general within the draft ‘Adult Highly Specialist Pain Management Services’, due for publication later in 2018. These will comprise a limited number of specialised centres in the UK, and only accessed via referral from Level 3 services. Within the context of pain from cancer and life-limiting disease, Level 4 services will be for:

Patients not responding to Level 3 pain services and who have a realistic possibility of improvement within Level 4 service.

Patients with pain directly associated with cancer or indirectly from its treatments, and other life-limiting disease, and which may not fall within the scope or expertise of palliative medicine or local pain services. For example those who require an interdisciplinary pain management approach delivered by a highly specialist pain management service.

Patients with complex and difficult to manage pain who may require more specific interventional treatment than are available at Level 3 services, e.g. cordotomy, intrathecal neurolytic block.

Young people (under 18yrs) with significant pain should also have access to pain services with the skills to manage their pain and will require liaison between paediatric services and these joint pain and palliative care services.

### 3.2. Composition and function of the Multi-Disciplinary Team

Level 3 services should have a Consultant in Pain Medicine (FFPMRCA or with equivalent recognised training) and a Consultant in Palliative Medicine, with formal links to Consultants in Medical and Clinical Oncology. The service should also have access to a nurse specialist, a clinical psychologist and a physical therapist in line with other Level 3 pain management services [32]. The British Pain Society and Royal College of Anaesthetists recommend that pain specialists regularly working in palliative care require recognition of this commitment in their job plan and that these sessions should be fully funded [28,32]. Job planning must include recognition of the fixed and variable commitment to this area of care and the associated additional SPA session (supporting professional activity) above and beyond core revalidation requirements for other areas of practice (e.g. Chronic Pain, Anaesthesia, etc.). A minimum of one DCC session (direct clinical care) and one SPA session for each consultant would act as a likely safeguard to clinical safety.

There should be a weekly MDT involving a Consultant in Pain Medicine and Consultant in Palliative Medicine at which referrals can be discussed and arrangements made for clinical review in a weekly outpatient clinic. The MDT can be held in person or virtually via video link. This core team should have access to advice from oncology, radiology, pharmacy and other disciplines as needed.

Level 4 services should have a minimum of two Consultants in Pain Medicine (FFPMRCA or with equivalent recognised training) and one Consultant in Palliative Medicine with the associated MDT that are experienced in assessing pain mechanisms and determining pain management in those with complex cancer-related pain [31,33]. There should be a weekly MDT involving a Consultant in Pain Medicine and Consultant in Palliative Medicine at which referrals can be discussed and arrangements made for clinical review in a weekly outpatient clinic. The number of clinical sessions required is likely to be similar to that of a Level 3 service, but may well be greater depending on the volume and complexity of patients. This team must be able to provide all the pain medicine related care needs of the patient throughout the process, including long term management where necessary (this may be a shared care model with local services) [31,33].

### 3.3. Clinical interventions

Level 3 and Level 4 pain management services should arrange urgent review of patients with severe uncontrolled pain (within 1 week of referral), consistent with NHS and IASP guidance [31, 40, 41]. The assessment will include confirmation of pain diagnosis and pain aetiology (using ICD-11 classification system [42]), the need for further investigations, and an agreed management plan consistent with patient goals and preferences.

Level 3 services will include local expertise in management of complex analgesic combinations (methadone, ketamine) including high dose opioids, and interventional procedures including peripheral nerve blocks (e.g. coeliac plexus, lumbar sympathectomy) and intrathecal neurolytic block. Other procedures may be offered within the competency of the Consultant in Pain Medicine and the expertise of staff and local infrastructure such as external spinal infusions. Level 3 services should link regionally in order to maximise the skills and management options available to patients.

Level 4 services will also be Level 3 providers but will have additional skills and expertise to provide highly specialist pain services as found in the service specification. These would include specific multidisciplinary assessment and management of patients who have a realistic potential for improvement but have not responded to Level 3 services. These would include other neurolytic procedures where expertise is not available within specialist pain management (Level 3) services, inpatient drug optimisation (including opioid management programs) [33], neuromodulation, implantable spinal infusions and some centres will offer cordotomy. In addition, Level 4 services

should offer access to rehabilitative programmes, and expertise in managing distress and other behaviours related to poorly controlled medication use. Provision for out-of-hours management of neuraxial infusions should be decided by local protocols and agreement [33,40].

### 3.4. Patient centred outcomes for pain from cancer and other disease

Key priorities in pain management strategies for patients with cancer and life-limiting disease should be to help patients achieve a balance between pain and adverse effects of analgesia to optimise physical function, and support for self-management [10]. In this context, greater collaboration between pain management, oncology and palliative care services could improve outcomes by offering a broader range of non-drug treatment options or interventional management.

All oncology and palliative care professionals (Level 2) should ensure that their services are able to meet standards described by the Faculty of Pain Medicine [34] and NICE Guidance on Opioids in Palliative Care [35]. Although these standards are incorporated into the Care Quality Commission inspection framework for end of life care [36], they are applicable to all patients with pain from cancer and other advanced diseases.

The Faculty of Pain Medicine's standards on cancer pain [34] are as follows:

1. *Patients with cancer-related pain must receive a pain assessment when seen by a healthcare professional, which at a minimum establishes aetiology, intensity and the impact of any pain that they report.*
2. *Access to analgesia must be available within 24 hours following a pain assessment which directs the need for analgesia. This must include access to a prescriber as well as access to a dispensed prescription.*
3. *Patients and carers must receive adequate information on the use of analgesics, especially strong opioids (in accordance with NICE guidance on Opioids in Palliative Care). This must cover how to take analgesia, the likely effectiveness of this, how to monitor side effects, plans for further follow-up, and how to get help - especially out of hours.*
4. *Patients and carers must be referred for specialist support if pain is not well controlled despite initial management. Specialist support must be available in each region in the form of palliative care services, oncology services (including radiotherapy), and specialist pain services*

The NHS outcomes framework will guide the use of clinical outcome measures and standards of care for Level 3 and Level 4 pain services. There will be particular emphasis on identifying improvements in quality of life and the impact of pain on daily lives of patients and their families using Patient (and carer) Reported Outcome Measures recommended by the Faculty of Medicine and British Pain Society [43].

## NHS outcomes framework

<b>Domain 1</b>	Preventing people from dying prematurely	√
<b>Domain 2</b>	Enhancing quality of life for people with long-term conditions	√
<b>Domain 3</b>	Helping people to recover from episodes of ill-health or following injury	√
<b>Domain 4</b>	Ensuring people have a positive experience of care	√
<b>Domain 5</b>	Treating and caring for people in safe environment and	√

Level 3 and Level 4 services should ensure that they contribute to setting standards of care for patients with pain from cancer and life-limiting disease within their local health care community. The European Pain Federation (EFIC) has developed 10 standards for the management of cancer-related pain [44] which can guide local care delivery:

**Standard 1.** Patients with a history of cancer should be routinely screened for pain at every engagement with a health care professional.

**Standard 2.** Patients identified with cancer-related pain should receive a pain assessment when seen by a healthcare professional, which at a minimum classifies the cause of pain based on proposed ICD-11 taxonomy and establishes the intensity and impact on quality of life of any pain that they report.

**Standard 3.** A multimodal pain management plan should be agreed with the patient that explains the causes of their pain and its likely prognosis, the need for further investigations, the multimodal treatment options, and includes the patient's preferences and goals for treatment.

**Standard 4.** Patients should receive tailored multimodal treatment which reduces the pain and its impact on daily living and that may include a combination of medicines, nonpharmacological treatments, oncological interventions, physical rehabilitation, and psychosocial or spiritual support.

**Standard 5.** Support and advice for self-management should be provided.

**Standard 6.** The pain management plan should be reviewed regularly to assess outcomes and plan longer-term care.

**Standard 7.** Patients should be referred for more specialist advice and treatment if pain is not improving within a short time or if they are experiencing intolerable side-effects of analgesia.

**Standard 8.** Healthcare professionals who treat patients with cancer should receive ongoing education and training in order to undertake basic pain assessment, initiate basic management, and learn about correctly referring for more specialist support.

**Standard 9.** Regular review of service outcomes for all patients with cancer pain should be in place.

**Standard 10.** Each EFIC chapter should have national evidence or consensus based guidelines in place for cancer-related pain.

### 3.5. Audit, research and education

The British Pain Society [28] recommends that combined pain and palliative care cancer pain services should undertake additional activities including joint educational seminars (local and national), joint audit and research projects and publications, and attendance at national and international meetings. Level 3 and Level 4 services should have a role in ensuring that the importance of pain control is appropriately included in relevant training, as part of university undergraduate and postgraduate medical curricula.

### 3.6. Competencies

The Faculty of Medicine has published core competencies for managing cancer pain by all practitioners in Pain Medicine and more advanced competencies for those involved in delivering a cancer pain service, which are endorsed by the Association for Palliative Medicine [37]. It is important that nurses, physiotherapists, pharmacists and other healthcare professionals introduce the principles of multimodal pain management into their curricula.

Training curricula for Palliative Medicine, Medical Oncology and Clinical Oncology [45-47] should broadly map to the core competencies for cancer pain management in the Faculty of Pain Medicine document [37] rather than the advanced competencies. There is opportunity to share a common curriculum in cancer pain management for all palliative care and oncology trainees in order to provide a Level 2 service. Advanced pain training should be available to trainees in palliative medicine and oncology to develop skills as part of a Level 3 and 4 services.

## References

1. Cancer Research UK Cancer Mortality Statistics. Secondary Cancer Mortality Statistics 2015. <http://www.cancerresearchuk.org/health-professional/cancer-statistics/mortality>.
2. Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, Cohen R, Dow L. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. *Ann Oncol*. 2009 Aug;20(8):1420-33
3. Paice JA. Chronic treatment-related pain in cancer survivors. *Pain* 2011;152(Supplement):S84–S89.
4. Seretny M, Currie G L, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin L, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. *Pain* 2014;155(12):2461–2470.
5. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. *Annals of Oncology* 2007;18(9):1437-49.
6. Hackett J, Godfrey M, Bennett MI. Patient and caregiver perspectives on managing pain in advanced cancer: A qualitative longitudinal study. *Palliative Medicine* 2016;30(8):711-9
7. Bender JL, Hohenadel J, Wong J, Katz J, Ferris LE, Shobbrook C, Warr D, Jadad AR. What patients with cancer want to know about pain: a qualitative study. *J Pain Symptom Manage*. 2008;35(2):177-87
8. Gibbins J, Bhatia R, Forbes K, Reid CM. What do patients with advanced incurable cancer want from the management of their pain? A qualitative study. *Palliat Med*. 2014 Jan;28(1):71-8.
9. Manzano-Santaella A, Ziegler L, Bennett MI. Exploring interference from analgesia in patients with cancer pain: A Qualitative Study. *Journal of Clinical Nursing* 2014;23;(13-14):1877-1888
10. Bennett MI. Mechanism-based cancer-pain therapy. *PAIN* 2017;158 Suppl 1:S74-S78
11. Greco MT, Roberto A, Corli O, et al. Quality of cancer pain management: an update of a systematic review of under-treatment of patients with cancer. *Journal of Clinical Oncology*: 2014;32(36):4149-54.
12. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. *Ann Oncol*. 2008;19(12):1985-91
13. Zeigler LE, Mulvey MR, Blenkinsopp A, Petty D, Bennett MI. Opioid prescribing for cancer patients in the last year of life: a longitudinal population cohort study *PAIN* 2016 157(11):2445-2451
14. Higginson IJ, Gao W. Opioid prescribing for cancer pain during the last 3 months of life: associated factors and 9-year trends in a nationwide United Kingdom cohort study. *J Clin Oncol* 2012;30(35):4373-9
15. Gomes B, Higginson IJ, Calanzani N, Cohen J, Deliens L, et al. Preferences for place of death if faced with advanced cancer: a population survey in England, Flanders, Germany, Italy, the Netherlands, Portugal and Spain. *Ann Oncol* 23: 2012: 2006–2015
16. VOICES questionnaire data: <http://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthcaresystem/bulletins/nationalsurveyofbereavedpeoplevoices/2015-07-09>
17. Adam R, Wassell P, Murchie P. Why do patients with cancer access out-of-hours primary care? A retrospective study. *British Journal of General Practice* 2014;64(619):e99-104.
18. Kavalieratos D, Corbelli J, Zhang D, Dionne-Odom JN, Ernecoff NC, Hanmer J, Hoydich ZP, Ikejiani DZ, Klein-Fedyshin M, Zimmermann C, Morton SC, Arnold RM, Heller L, Schenker Y. Association Between Palliative Care and Patient and Caregiver Outcomes: A Systematic Review and Metaanalysis. *JAMA* 2016;316(20):2104-2114.

19. Gomes B, Calanzani N, Curiale V, McCrone P, Higginson IJ. Effectiveness and cost-effectiveness of home palliative care services for adults with advanced illness and their caregivers. *Cochrane Database Syst Rev* 2013;(6):CD007760.
20. Gaertner J, Siemens W, Meerpohl JJ, Antes G, Meffert C, Xander C, Stock S, Mueller D, Schwarzer G, Becker G. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and metaanalysis. *BMJ* 2017;357:j2925.
21. Department of Health. End of Life Care Strategy: Promoting high quality care for all adults at the end of life. London: HMSO, 2008.
22. NICE Quality Standard: End of Life Care for adults (QS13). National Institute for Health and Care Excellence, 2011
23. Care Quality Commission (CQC). Inequalities and Variations in End of Life Care. London: CQC, 2014.
24. End-of-life care and physician-assisted dying. British Medical Association, London 2015.
25. British Medical Association. Improving analgesic use to support pain management at the end of life. BMA, London 2017
26. Moens K, Higginson IJ, Harding R. Are There Differences in the Prevalence of Palliative Care-Related Problems in People Living With Advanced Cancer and Eight Non-Cancer Conditions? A Systematic Review. *Journal of Pain and Symptom Management* 2014;48:660-677
27. Raphael JH, Ahmedzai S, Hester J, Urch C, Barrie J, Williams J, Farquhar-Smith P, Fallon M, Hoskin P, Robb K, Bennett MI, Haines R, Johnson M, Bhaskar A, Chong S, Duarte R, Sparkes E. Cancer Pain: Part 1: Pathophysiology; Oncological, Pharmacological, and Psychological Treatments: A Perspective from the British Pain Society endorsed by the UK Association for Palliative Medicine and the Royal College of General Practitioners. *Pain Medicine* 2010; 11(5):742-764
28. Raphael J, Hester J, Ahmedzai S, Barrie J, Farquhar-Smith P, Williams J, Urch C, Bennett MI, Robb K, Simpson B, Pittler M, Wider B, Ewer-Smith C, Decourcy J, Young A, Lioffi C, McCullough R, Rajapakse D, Johnson M, Duarte R, Sparkes E. Cancer Pain: Part 2: Physical, Interventional and Complimentary Therapies; Management in the Community; Acute, Treatment-Related and Complex Cancer Pain: A Perspective from the British Pain Society Endorsed by the UK Association for Palliative Medicine and the Royal College of General Practitioners. *Pain Medicine* 2010; 11(6):872-896.
29. O'Brien T, Kane CM. Pain services and palliative medicine – an integrated approach to pain management in the cancer patient. *British Journal of Pain* 2014;8(4) 163–171.
30. Allsop MJ, Ziegler LE, Mulvey MR, Russell S, Taylor R, Bennett MI. Duration and determinants of hospice-based specialist palliative care for patients in the UK. A national retrospective cohort study. *Palliative Medicine* 2018;32(8):1322–1333
31. NHS England. Adult Highly Specialist Pain Management Services (1767). NHS England; London 2018.
32. Faculty of Pain Medicine. Local Commissioning of Specialist Services for pain: Recommendations of the Faculty of Pain Medicine. London, 2013.
33. NHS England. Clinical Commissioning Policy: Intrathecal Pumps for Treatment of Severe Cancer Pain. NHS England D08/P/b. London 2015
34. Faculty of Pain Medicine. Core Standards for Pain Management Services in the UK. London 2015. <https://www.rcoa.ac.uk/node/21140>
35. National Institute for Health and Clinical Excellence. Safe and effective prescribing of strong opioids for pain in palliative care of adults. (Clinical guideline 140.) 2012. [www.nice.org.uk/CG140](http://www.nice.org.uk/CG140)

36. Care Quality Commission. Inspection framework for End of Life Care. London, 2016.  
<http://www.cqc.org.uk/sites/default/files/20170629-IH-end-of-life-care-core-serviceframework.pdf>
37. Faculty of Pain Medicine. Guidance on competencies for management of Cancer Pain in adults. London 2016. <https://www.rcoa.ac.uk/system/files/FPM-GuidanceCP.pdf>
38. NICE Guidance on Cancer Services (CSG4). Improving Supportive and Palliative Care for Adults with Cancer. The Manual. National Institute for Health and Care Excellence, 2004.
39. Pain Management Services: Planning for the Future Guiding clinicians in their engagement with Commissioners. Royal College of General Practitioners, London 2013.
40. Royal College of Anaesthetists. Guidance on the provision of anaesthetic services: Chapter 12 Anaesthesia services for chronic pain management. Royal College of Anaesthetists, London 2013.
41. International Association for the Study of Pain (2018). Task Force on Wait-Times. Summary and Recommendations. [https://www.iasp-pain.org/files/Content/NavigationMenu/EducationalResources/IASP\\_Wait\\_Times.pdf](https://www.iasp-pain.org/files/Content/NavigationMenu/EducationalResources/IASP_Wait_Times.pdf)
42. Bennett MI, Kaasa S, Barke A, Korwisi B, Rief W, Treede RD, and the ICD-11 task force. The IASP classification of chronic pain: Chronic cancer-related pain. PAIN (in press)
43. Outcome Measures Working Party report. Faculty of Pain Medicine and British Pain Society, London 2018
44. Bennett MI, Eisenberg E, Ahmedzai SH, Bhaskar A, O'Brien T, Mercadante S, Škvarč NK, Vissers K, Wirz S, Wells C, Morlion B. Standards for the management of cancer-related pain across Europe. A position paper from the EFIC Task Force on Cancer Pain. European Journal of Pain (published online)
45. Joint Royal Colleges of Physicians Training Board. Specialty Training Curriculum for Palliative Medicine, Royal College of Physicians London 2015
46. Joint Royal Colleges of Physicians Training Board. Specialty Training Curriculum for Medical Oncology. Royal College of Physicians, London 2010
47. The Royal College of Radiologists. Specialty training curriculum for clinical oncology. London: The Royal College of Radiologists, 2016



**The Faculty of Pain Medicine**  
of the Royal College of Anaesthetists

Churchill House  
35 Red Lion Square  
London WC1R 4SG

tel: 020 7092 1682 or 020 7092 1746  
email: [contact@fpm.ac.uk](mailto:contact@fpm.ac.uk)

[www.fpm.ac.uk](http://www.fpm.ac.uk)